EGFR and non-small cell lung carcinoma: Initially introduced to the field of NSCLC for identifying EGFR-sensitizing mutations, ctDNA testing has since evolved—particularly with the advent of NGS—to support comprehensive genomic profiling, enabling broader assessment of tumor heterogeneity and resistance mechanisms.